Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Study of AG-120 and AG-881 in Recurrent IDH1 Mutant Low Grade Glioma
NCT03343197Phase 1Completed
- Sponsor
- Servier
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivosidenib and vorasidenib in glioma (3 arms), sponsored by Servier. Primary endpoint: 2-HG concentration in surgically resected tumors at 4 weeks. Started Mar 2018; status: completed.
02
Drugs
ivosidenibvorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03343197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343197.